Hospital
Portage Hospital LLC
Portage Hospital LLC was paid $5.85M by Medicaid between Jan 2018 and Dec 2024, across 153 billing codes. Its largest line is 99285, emergency room visit (most serious) — 23% of everything it billed.
33Billing provider infoPORTAGE HOSPITAL LLC
HANCOCK, MI 49930
HANCOCK, MI 49930
33aNPI1245667229assigned 10/04/2013
33bProvider typeGeneral Acute Care Hospital
28Total paid$5.85M
24GClaims252,108
24DCodes billed153
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Michigan
Rank by total paid#69 of 86
Median peer was paid$21.55M
This provider vs. median0.3×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official LAWRENCE, CHARLOTTE controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 38,930 | $757K | |
| 2019 | 35,061 | $723K | |
| 2020 | 29,842 | $652K | |
| 2021 | 39,097 | $991K | |
| 2022 | 38,319 | $982K | |
| 2023 | 38,882 | $935K | |
| 2024incomplete | 31,977 | $808K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 23% | 4,278 | 3,926 | $1.37M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 15% | 6,878 | 6,536 | $872K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 13% | 3,748 | 3,555 | $735K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 5.3% | 10,528 | 3,796 | $310K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 3.6% | 2,212 | 2,036 | $213K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 3.6% | 5,139 | 1,922 | $210K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 2.8% | 4,451 | 1,812 | $164K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.7% | 2,259 | 2,181 | $159K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.7% | 1,054 | 1,020 | $156K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 2.6% | 1,566 | 1,130 | $152K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 1.8% | 1,685 | 1,083 | $102K |
| 71046 | Radiologic examination, chest; 2 views | 1.5% | 2,363 | 2,263 | $88K |
141 more codes
| 96375 | Therapeutic injection; each additional sequential IV push | 1.3% | 2,344 | $76K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.1% | 1,969 | $65K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.1% | 1,461 | $64K |
| 84443 | Thyroid stimulating hormone (TSH) | 1.0% | 8,350 | $60K |
| 80053 | Comprehensive metabolic panel | 1.0% | 18,293 | $59K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 656 | $58K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 3,465 | $58K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 2,421 | $57K |
| 80061 | Lipid panel | <1% | 5,079 | $57K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 21,526 | $52K |
| 36415 | Collection of venous blood by venipuncture | <1% | 29,889 | $49K |
| 71045 | Radiologic examination, chest; single view | <1% | 1,032 | $40K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,664 | $29K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,608 | $28K |
| 41899 | Unlisted procedure, dentoalveolar structures | <1% | 12 | $28K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 1,065 | $27K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 1,840 | $24K |
| G0330 | Facility services for dental rehabilitation procedure(s) performed on a patient who requires monitored anesthesia (e.g., general, intravenous sedation (monitored anesthesia care) and use of an operating room | <1% | 13 | $22K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 286 | $22K |
| G0145 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision | <1% | 1,349 | $21K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 3,829 | $19K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 666 | $18K |
| 97162 | <1% | 338 | $18K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 341 | $16K |
| 84439 | <1% | 3,526 | $16K | |
| 86900 | <1% | 517 | $15K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 999 | $15K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 4,695 | $13K |
| 82728 | <1% | 2,036 | $13K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 228 | $12K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 663 | $12K |
| 87088 | <1% | 4,106 | $12K | |
| 87186 | <1% | 2,460 | $11K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 89 | $10K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 2,394 | $9K |
| 76801 | <1% | 159 | $9K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 117 | $9K |
| 87806 | <1% | 944 | $9K | |
| 76830 | Ultrasound, transvaginal | <1% | 145 | $8K |
| 73610 | <1% | 364 | $8K | |
| 83655 | <1% | 1,016 | $7K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 2,562 | $7K |
| 87081 | <1% | 2,460 | $7K | |
| 82607 | <1% | 948 | $7K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 92 | $6K |
| 81001 | <1% | 8,691 | $6K | |
| 86803 | <1% | 1,291 | $6K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 44 | $5K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 1,874 | $5K |
| 87070 | <1% | 1,563 | $5K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 1,177 | $5K |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 990 | $5K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 12 | $5K |
| C8929 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography | <1% | 12 | $5K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 98 | $4K |
| 85027 | <1% | 1,615 | $4K | |
| 86850 | <1% | 594 | $4K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 308 | $4K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 62 | $4K |
| 73630 | <1% | 230 | $4K | |
| 80305 | <1% | 1,289 | $3K | |
| 97161 | <1% | 64 | $3K | |
| 82570 | <1% | 1,257 | $3K | |
| 73110 | <1% | 108 | $3K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 1,020 | $3K |
| 86140 | <1% | 1,569 | $3K | |
| 73562 | <1% | 107 | $2K | |
| 83735 | <1% | 3,884 | $2K | |
| 86592 | <1% | 815 | $2K | |
| 85652 | <1% | 2,082 | $2K | |
| 73130 | <1% | 114 | $2K | |
| 87340 | <1% | 816 | $2K | |
| 85610 | <1% | 2,095 | $2K | |
| 84481 | <1% | 204 | $2K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 29 | $2K |
| 82043 | <1% | 533 | $2K | |
| 0012A | <1% | 45 | $2K | |
| 83540 | <1% | 455 | $2K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 47 | $1K |
| 84703 | <1% | 3,229 | $1K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 12 | $1K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 12 | $1K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 200 | $1K |
| 87077 | <1% | 312 | $1K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 12 | $1K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 198 | $1K |
| 83690 | <1% | 2,009 | $1K | |
| 74019 | <1% | 70 | $1K | |
| 0011A | <1% | 70 | $922.95 | |
| 73030 | <1% | 47 | $891.84 | |
| 84702 | <1% | 144 | $761.53 | |
| 00170 | Anesthesia for intraoral procedures, including biopsy | <1% | 13 | $757.37 |
| 84145 | <1% | 1,155 | $755.85 | |
| 86038 | <1% | 174 | $711.18 | |
| 82950 | <1% | 255 | $696.84 | |
| Q0111 | Wet mounts, including preparations of vaginal, cervical or skin specimens | <1% | 89 | $686.03 |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 544 | $605.87 |
| 85730 | <1% | 814 | $471.75 | |
| 87581 | <1% | 44 | $460.56 | |
| 87486 | <1% | 44 | $460.56 | |
| 87210 | <1% | 194 | $438.15 | |
| 83550 | <1% | 96 | $420.21 | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 12 | $419.40 |
| 72100 | <1% | 15 | $387.88 | |
| 86756 | <1% | 138 | $382.78 | |
| 83615 | <1% | 201 | $343.51 | |
| 85378 | <1% | 207 | $236.70 | |
| 73502 | <1% | 13 | $220.67 | |
| 83880 | <1% | 26 | $206.18 | |
| 86704 | <1% | 38 | $204.67 | |
| 84484 | <1% | 1,515 | $190.38 | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 216 | $166.34 |
| 88304 | <1% | 27 | $154.90 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 2,105 | $106.24 |
| 83605 | <1% | 1,807 | $98.69 | |
| 82550 | <1% | 209 | $91.20 | |
| 82077 | <1% | 731 | $90.79 | |
| 82652 | <1% | 13 | $45.82 | |
| 86430 | <1% | 13 | $34.30 | |
| 86431 | <1% | 26 | $34.28 | |
| 82042 | <1% | 12 | $29.82 | |
| 80076 | <1% | 16 | $24.30 | |
| 84550 | <1% | 16 | $15.84 | |
| 80143 | <1% | 298 | $10.40 | |
| 86762 | <1% | 13 | $9.04 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | 0% | 3,274 | $0.00 |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 0% | 324 | $0.00 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 0% | 335 | $0.00 |
| J2704 | Injection, propofol, 10 mg | 0% | 2,385 | $0.00 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 0% | 1,297 | $0.00 |
| 86901 | 0% | 516 | $0.00 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 0% | 804 | $0.00 |
| 0240U | 0% | 647 | $0.00 | |
| A9270 | Non-covered item or service | 0% | 617 | $0.00 |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | 0% | 40 | $0.00 |
| J1170 | Injection, hydromorphone, up to 4 mg | 0% | 88 | $0.00 |
| J0690 | Injection, cefazolin sodium, 500 mg | 0% | 43 | $0.00 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | 0% | 2,742 | $0.00 |
| 80179 | 0% | 294 | $0.00 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | 0% | 13 | $0.00 |
| 99001 | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialLAWRENCE, CHARLOTTE (SECRETARY)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.